Finosis Healthcare develops, manufactures, markets and distributes a broad spectrum of pharmaceuticals medicine under generics.

Finosis is committed to product development and has built a deep pipeline that includes a substantial number of product applications pending at the FDA in addition to a large number of product candidates in various stages of development.  Finosis has grown substantially, with a top line compounded annual growth rate of more than 25% since 2001.  The company intends to grow its business organically, as well as by acquiring complementary products or companies and forming strategic relationships.

Finosis has targeted three areas of its business for expansion. The strategy for its base generics business is to commercialize products in its pipeline, develop products with market barriers to entry, acquire complementary products and form strategic relationships. For its controlled substance business, the company intends to continue to invest in the development of higher margin products, with a focus on novel forms of delivery, to become a dominant player in the India. Lastly, the company will continue to ramp up its branded products business.

The company anticipates that the demand for its generic medications, narcotics and controlled drugs, and branded products will fueled. Lannett’s strong track record of regulatory compliance and manufacturing excellence, combined with strong management team, position the company well for the future.